

BANDO AIFA 2006

Link a Progetto e CV	Codice	Responsabile Scientifico	Istituzione	Titolo	Budget Indicato nel Contratto	Budget Ridotto per Riduzione Numerosità Campionaria	Extra Budget Autorizzato per Farmaco o Assicurazione
http://www.agenziafarmaco.gov.it/sites/default/files/1_AMADORI_DINO.zip	FARM6FJJAY	AMADORI DINO	Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori	Sequential treatment strategy for metastatic colorectal cancer: a phase III prospective randomized multicenter study of chemotherapy (CT) with or without bevacizumab as first-line therapy followed by two phase III randomized studies of CT alone or CT plus bevacizumab with or without cetuximab as second-line therapy.	950.000,00	852.000,00	
http://www.agenziafarmaco.gov.it/sites/default/files/2_AMMASSARI_ADRIANA.zip	FARM637CHK	AMMASSARI ADRIANA	Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani.I.R.C.C.S.	Prospective randomized controlled multi-dimensional trial on an informative and educational program for the appropriate use on antiretroviral drugs focused on patients and patient associations: effect on adherence improvement.	542.500,00		
http://www.agenziafarmaco.gov.it/sites/default/files/3_ARDIZZONI_ANDREA.zip	FARM6PMFJM	ARDIZZONI ANDREA	Gruppo Oncologico Italiano di Ricerca Clinica - GOIRC	Multicenter phase III randomized study of cisplatin and etoposide with or without bevacizumab as first-line treatment in extensive stage (ED) small cell lung cancer (SCLC)	240.000,00		
http://www.agenziafarmaco.gov.it/sites/default/files/4_BARBUI_TIZIANO.zip	FARM6YNXAN	BARBUI TIZIANO	Azienda Ospedaliera Ospedali Riuniti Di Bergamo	Intensity of CYToreductive therapy to prevent cardiovascular events in patients with Polycythemia vera (PV) – CYTO-PV	300.000,00		
http://www.agenziafarmaco.gov.it/sites/default/files/5_BERNARDI_MAURO.zip	FARM6P824B	BERNARDI MAURO	Università di Bologna "Alma Mater Studiorum"- Dipartimento di Medicina Interna, Cardioangiologia Epatologia	The use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: a multicentric, open-label randomized clinical trial	898.800,00	838.920,00	
http://www.agenziafarmaco.gov.it/sites/default/files/6_BERNI_CANANI_ROBERTO.zip	FARM6FJ728	BERNI CANANI ROBERTO	Università degli Studi di Napoli "Federico II"- Dip. di Pediatria	Therapeutic efficacy of butyrate in pediatric patients with congenital chloride diarrhea	151.500,00		
http://www.agenziafarmaco.gov.it/sites/default/files/7_BONATI_MAURIZIO.zip	FARM6Z3KX9	BONATI MAURIZIO	Istituto di ricerche farmacologiche "Mario Negri"	Prescription, efficacy, and safety of psychotropic drugs in the Italian paediatric population	645.623,00		
http://www.agenziafarmaco.gov.it/sites/default/files/8_BONINI_STEFANO.zip	FARM6AS8AW	BONINI STEFANO	Università Campus Bio-Medico di Roma	Multicenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eye drop treatment on patients with ocular cicatricial pemphigoid.	270.000,00	236.252,00	

Link a Progetto e CV	Codice	Responsabile Scientifico	Istituzione	Titolo	Budget Indicato nel Contratto	Budget Ridotto per Riduzione Numerosità Campionaria	Extra Budget Autorizzato per Farmaco o Assicurazione
http://www.agenziafarmaco.gov.it/sites/default/files/9_BORTOLUS_RENATA.zip	FARM6KWTCT	BORTOLUS RENATA	Azienda Ospedaliera Universitaria Integrata di Verona	RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFICACY OF HIGH DOSE OF FOLIC ACID TO PREVENT THE OCCURRENCE OF CONGENITAL MALFORMATIONS	916.500,00	830.130,00	
http://www.agenziafarmaco.gov.it/sites/default/files/10_CALABRESI_PAOLO.zip	FARM6TT8SP	CALABRESI PAOLO	Dipartimento di Specialita' Medico-Chirurgiche e Sanita' Pubblica	SODIUM VALPROATE IN THE TREATMENT OF MEDICATION OVERUSE HEADACHE:A CONTROLLED RANDOMIZED CLINICAL TRIAL	525.000,00	458.727,00	
http://www.agenziafarmaco.gov.it/sites/default/files/11_CALABR%C3%92_RAFFAELE.zip	FARM6HCEM5	CALABRÒ RAFFAELE	Seconda Università degli Studi di Napoli	Arterial Hypertension After Successful Aortic Decoarctation: Atenolol vs Enalapril Comparison of Efficacy and Tolerability in Pediatric Age.	168.000,00	142.000,00	
http://www.agenziafarmaco.gov.it/sites/default/files/12_CALTAGIRONE_CARLO.zip	FARM6ZEMBP	CALTAGIRONE CARLO	Fondazione IRCCS Santa Lucia	Mortality of elderly using conventional and non conventional antipsychotic drugs for the behavioral and psychological symptoms of dementia and for other psychical disorders	360.000,00		
http://www.agenziafarmaco.gov.it/sites/default/files/13_CASCINU_STEFANO.zip	FARM6XB38F	CASCINU STEFANO	Fondazione Giscad per la Ricerca sui Tumori	Open-label randomized, parallel group, phase III, multicentric trial comparing two different sequences of therapy (IRINOTECAN/CETUXIMAB followed by FOLFOX-4 vs FOLFOX-4 followed by IRINOTECAN/CETUXIMAB) in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab as first line chemotherapy	395.250,00	274.780,00	
http://www.agenziafarmaco.gov.it/sites/default/files/14_CICCONE_ALFONSO.zip	FARM6LN3KS	CICCONE ALFONSO	Azienda Ospedaliera Ospedale Niguarda Ca' Granda	SYNTHESIS: A RANDOMIZED CONTROLLED TRIAL ON INTRA-ARTERIAL VERSUS INTRAVENOUS THROMBOLYSIS IN ACUTE ISCHEMIC STROKE	550.000,00		
http://www.agenziafarmaco.gov.it/sites/default/files/15_CITERIO_GIUSEPPE.zip	FARM6FKJKK	CITERIO GIUSEPPE	Azienda Ospedaliera S. Gerardodi Monza	Anesthesiological strategies in elective craniotomy: randomized, equivalence, open trial	551.880,00		
http://www.agenziafarmaco.gov.it/sites/default/files/16_CONTE_PIERFRANCO.zip	FARM62MC97	CONTE PIERFRANCO	Università degli Studi di Modena	Short-HER: multicentric randomised phase III trial of adjuvant chemotherapy plus 3 vs 12 months of trastuzumab in breast cancer patients with HER2 positive disease	1.614.600,00	1.459.620,00	

Link a Progetto e CV	Codice	Responsabile Scientifico	Istituzione	Titolo	Budget Indicato nel Contratto	Budget Ridotto per Riduzione Numerosità Campionaria	Extra Budget Autorizzato per Farmaco o Assicurazione
http://www.agenziafarmaco.gov.it/sites/default/files/17_CORCHIA_CARLO.zip	FARM6NJ3TZ	CORCHIA CARLO	Ospedale pediatrico "Bambino Gesù"	Double blind randomized controlled study on the benefit-risk profile of the administration of Sildenafil (Viagra®) in the treatment of at term or late preterm newborn infants with severe respiratory disorders and pulmonary hypertension	240.000,00		
http://www.agenziafarmaco.gov.it/sites/default/files/18_CORRADO_ANTONIO.zip	FARM6YHYW4	CORRADO ANTONIO	Azienda Ospedaliero-Universitaria Careggi Firenze	LONG-TERM OXYGEN THERAPY (LTOT) IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS WITH MODERATE CHRONIC HYPOXEMIA AND CHRONIC HEART FAILURE	1.133.000,00		
http://www.agenziafarmaco.gov.it/sites/default/files/19_DEL_MASTRO_LUCIA.zip	FARM6N78KN	DEL MASTRO LUCIA	Istituto Nazionale per la Ricerca sul Cancro	EFFICACY AND TOXICITY OF TRASTUZUMAB AT THE MAINTAINING DOSE OF 1 MG/KG/WEEK VS THE STANDARD DOSE OF 2 MG/KG/WEEK IN COMBINATION WITH CHEMOTHERAPY IN METASTATIC BREAST CANCER PATIENTS. A PHASE III MULTICENTER STUDY.	608.850,00		
http://www.agenziafarmaco.gov.it/sites/default/files/20_DI_ROCCO_MAJA.zip	FARM6JBLZ2	DI ROCCO MAJA	Istituto "Gaslini" Genova	Multicenter randomized study to assess the efficacy and the safety of two therapeutic regimens (high dose of imiglucerase versus co-administration of imiglucerase and miglustat) in type I Gaucher disease patients who have not responded to previous treatment with low dose imiglucerase	171.750,00		
http://www.agenziafarmaco.gov.it/sites/default/files/21_FALDELLA_GIACOMO.zip	FARM63TMS3	FALDELLA GIACOMO	Azienda Ospedaliero Universitaria Policlinico S. Orsola Malpighi	EFFICACY AND SAFETY OF CONTINUOUS INFUSION OF FENTANYL FOR PAIN CONTROL IN PRETERM NEWBORNS ON MECHANICAL VENTILATION	200.000,00	130.000,00	
http://www.agenziafarmaco.gov.it/sites/default/files/22_FIORILLI_MASSIMO.zip	FARM6KMZFY	FIORILLI MASSIMO	Università "La Sapienza" Roma Dipartimento Di Medicina Clinica	EVALUATION OF THE BENEFIT/COST/SAFETY PROFILE OF LOW-DOSE ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB) TREATMENT FOR REFRACTORY MIXED CRYOGLOBULINEMIA	240.000,00		
http://www.agenziafarmaco.gov.it/sites/default/files/23_FRATICELLI_PAOLO.zip	FARM69JAJ9	FRATICELLI PAOLO	Azienda Ospedaliero Universitaria Ospedali Riuniti "Umberto I G.M. Lancisi – G. Salesi	Low-dose Oral Imatinib in the Treatment of Scleroderma Pulmonary Involvement: a Phase II pilot study.	250.000,00		

Link a Progetto e CV	Codice	Responsabile Scientifico	Istituzione	Titolo	Budget Indicato nel Contratto	Budget Ridotto per Riduzione Numerosità Campionaria	Extra Budget Autorizzato per Farmaco o Assicurazione
http://www.agenziafarmaco.gov.it/sites/default/files/24_GASPARINI_GIAMPIETRO.zip	FARM6L9TFK	GASPARINI GIAMPIETRO	Collegio Italiano dei Primari Oncologi Medici OspedaliериGenova	A RANDOMIZED TRANSLATIONAL PHASE III STUDY: OPTIMIZATION OF THE FOLFIRI SCHEDULE IN COMBINATION WITH BEVACIZUMAB FOR THERAPY OF METASTATIC COLORECTAL CANCER (MCC), BASED ON THE GENETIC POLIMORPHISMS (PHARMACOGENETIC EVALUATION) AND ANALYSIS OF CIRCULATING BIOMARKERS. STUDY COORDINATED BY THE C.I.P.O.M.O. ASSOCIATION	383.666,00		
http://www.agenziafarmaco.gov.it/sites/default/files/25_GATTINONI_LUCIANO.zip	FARM6JS3R5	GATTINONI LUCIANO	Fondazione Irccs – Ca' Granda Ospedale Maggiore Policlinico Mangiagalli Regina Elena	Efficacy of albumin administration for volume replacement in patients with severe sepsis or septic shock	1.098.300,00		
http://www.agenziafarmaco.gov.it/sites/default/files/26_LANDONI_GIOVANNI.zip	FARM6H73Z9	LANDONI GIOVANNI	Fondazione Centro San Raffaele del Monte Tabor	Cardiac protection by Sevoflurane in high risk patients undergoing cardiac surgery. A randomized controlled study.	105.725,00		
http://www.agenziafarmaco.gov.it/sites/default/files/27_MAZZAGLIA_GIAMPIERO.zip	FARM6JNEAM	MAZZAGLIA GIAMPIERO	Agenzia Regionale di Sanità Firenze	Assessing the risk/benefit profile of bisphosphonates therapy in the secondary prevention of osteoporotic fractures: results from a retrospective cohort study with regional claims databases.	577.500,00		
http://www.agenziafarmaco.gov.it/sites/default/files/28_MORETTI_COSTANZO.zip	FARM6XAXBR	MORETTI COSTANZO	Dipartimento di Medicina dei Sistemi – Università Degli Studi Di Roma Tor Vergata	Multicenter, randomized, double masked, controlled study on efficacy and safety of bicalutamide treatment in patients affected by familiar polycystic ovary syndrome (PCOS)	299.370,00	270.000,00	
http://www.agenziafarmaco.gov.it/sites/default/files/29_PALMIERI_GIOVANNELLA.zip	FARM6HJ7CA	PALMIERI GIOVANNELLA	Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica dell'Università degli Studi di Napoli Federico II	Phase II monitored clinical trial for evaluation of treatment of patients with Thymic Epithelial Tumours (TET) or Histiocitosi X (LCH) with Imatinib Mesylate	229.500,00	163.000,00	
http://www.agenziafarmaco.gov.it/sites/default/files/30_PAPI_ALBERTO.zip	FARM6BWSF9	PAPI ALBERTO	Università degli Studi di Ferrara	P.r.n. budesonide/formoterol combination versus regular budesonide/formoterol combination plus prn terbutaline in mild-moderate persistent asthma	1.109.000,00		
http://www.agenziafarmaco.gov.it/sites/default/files/31_PARODI_OBERDAN.zip	FARM659PTX	PARODI OBERDAN	Azienda Ospedaliera Ospedale Niguarda Ca' Granda	Effects of tetrahydrobiopterin (BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial	267.000,00		

Link a Progetto e CV	Codice	Responsabile Scientifico	Istituzione	Titolo	Budget Indicato nel Contratto	Budget Ridotto per Riduzione Numerosità Campionaria	Extra Budget Autorizzato per Farmaco o Assicurazione
http://www.agenziafarmaco.gov.it/sites/default/files/32_PESCI_ALBERTO.zip	FARM693KLZ	PESCI ALBERTO	Università degli Studi di Milano Bicocca	Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospective, controlled, randomized trial.	294.600,00	265.120,00	
http://www.agenziafarmaco.gov.it/sites/default/files/33_PIERANNUNZIO_DANIELA.zip	FARM6F47Z4	PIERANNUNZIO DANIELA	Istituto Superiore di Sanita'	Implementation and evaluation of a training programme on orphan drugs targeting patients' associations and families of patients with rare diseases.	180.000,00		
http://www.agenziafarmaco.gov.it/sites/default/files/34_PUCCI_NERI.zip	FARM6FYZB3	PUCCI NERI	Azienda Ospedaliero-Universitaria "A. Meyer" Firenze	MULTICENTRIC COMPARATIVE RANDOMIZED DOUBLE BLIND CROSS OVER STUDY WITH TACROLIMUS (FK506)0.1% EYEDROPS AND CYCLOSPORINE 1% EYEDROPS IN CHILDREN WITH SEVERE ACTIVE VERNAL KERATOCONJUNCTIVITIS, LASTING 7 WEEKS, FOLLOWED BY AN OPEN TRIAL LASTING 24 MONTHS TO EVALUATE LONG TERM EFFICACY AND SAFETY OF THE TREATMENT	160.000,00	155.000,00	
http://www.agenziafarmaco.gov.it/sites/default/files/35_RAMBALDI_ALESSANDRO.zip	FARM6223SS	RAMBALDI ALESSANDRO	Azienda Ospedaliera Ospedali Riuniti Di Bergamo	Randomized study comparing intravenous Busulfan (I.V. Bu; Busilvex®) plus Cyclophosphamide (BuCy2) versus intravenous Busulfan plus Fludarabine (BuFlu) as conditioning regimens prior to allogeneic hematopoietic stem cell transplantation in patients with Acute Myeloid Leukemia, Chronic Myeloid Leukemia and Myelodysplastic Syndrome	250.000,00		

Link a Progetto e CV	Codice	Responsabile Scientifico	Istituzione	Titolo	Budget Indicato nel Contratto	Budget Ridotto per Riduzione Numerosità Campionaria	Extra Budget Autorizzato per Farmaco o Assicurazione
http://www.agenziafarmaco.gov.it/sites/default/files/36_RAMBALDI_ALESSANDRO.zip	FARM6YMY2N	RAMBALDI ALESSANDRO EX BASSAN RENATO	Azienda Ospedaliera Ospedali Riuniti Di Bergamo	A multicentric randomized trial in adult patients with acute myelogenous leukemia (AML), to compare 1) a standard-dose versus high-dose remission induction regimen, and 2) an autologous blood stem cell transplantation versus an autologous blood stem cell-supported multicycle high-dose chemotherapy program, within a risk-oriented postremission strategy reserving allogeneic stem cell transplantation for high-risk cases	200.000,00		
http://www.agenziafarmaco.gov.it/sites/default/files/37_RASCHETTI_ROBERTO.zip	FARM68SY5C	RASCHETTI ROBERTO	Istituto Superiore di Sanita'	Alzheimer's Disease (AD) and antipsychotics: a long term, multicentre, double blind, randomised clinical trial	1.950.000,00		
http://www.agenziafarmaco.gov.it/sites/default/files/38_REDAELLI_TIZIANA.zip	FARM6Y35XM	REDAELLI TIZIANA	Azienda Ospedaliera Ospedale Niguarda Ca' Granda	EVALUATION OF THE TOLERABILITY AND EFFICACY OF ERYTHROPOIETIN (EPO) TREATMENT IN SPINAL SHOCK: COMPARATIVE STUDY VS METHYLPREDNISOLONE (MP)	259.500,00		
http://www.agenziafarmaco.gov.it/sites/default/files/39_REMUZZI%20GIUSEPPE.zip	FARM6WE4PP	REMUZZI GIUSEPPE EX MINGARDI GIULIO	Istituto di Ricerche Farmacologiche Mario Negri	A PROSPECTIVE, RANDOMIZED, OPEN LABEL, BLINDED END-POINT (PROBE) TRIAL TO EVALUATE WHETHER, AT COMPARABLE BLOOD PRESSURE CONTROL, ACE INHIBITOR THERAPY MORE EFFECTIVELY THAN NON RAS INHIBITOR THERAPY REDUCES CARDIOVASCULAR MORBIDITY AND MORTALITY IN CHRONIC HEMODIALYSIS PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY	828.170,00	577.335,00	
http://www.agenziafarmaco.gov.it/sites/default/files/40_RICCARDI_GABRIELE.zip	FARM6T9CET	RICCARDI GABRIELE	Societa' Italiana di Diabetologia	EFFECTS OF THE ADDITION OF A THIAZOLIDINEDIONE AS COMPARED WITH A SULFONYLUREA ON THE INCIDENCE OF MACROVASCULAR EVENTS IN TYPE 2 DIABETIC PATIENTS INADEQUATELY CONTROLLED WITH METFORMIN	2.400.000,00	2.146.048,00	

Link a Progetto e CV	Codice	Responsabile Scientifico	Istituzione	Titolo	Budget Indicato nel Contratto	Budget Ridotto per Riduzione Numerosità Campionaria	Extra Budget Autorizzato per Farmaco o Assicurazione
http://www.agenziafarmaco.gov.it/sites/default/files/41_SCANNI_ALBERTO.zip	FARM6F5JER	SCANNI ALBERTO	Azienda Ospedaliera Fatebenefratelli e Oftalmico	Optimization of erlotinib for the treatment of patients with advanced non-small cell lung cancer: an Italian randomized trial	1.772.370,00	1.264.622,00	
http://www.agenziafarmaco.gov.it/sites/default/files/42_SCARPA_MAUROZIO.zip	FARM6J8WS4	SCARPA MAURIZIO	Dipartimento di Pediatria "Salus Pueri"	EVALUATION OF THE EFFICACY OF ENZYME REPLACEMENT THERAPY IN PEDIATRIC PATIENTS AFFECTED BY MUCOPOLYSACCHARIDOSIS TYPE II (HUNTER SYNDROME)	223.200,00	198.333,00	
http://www.agenziafarmaco.gov.it/sites/default/files/43_SORGE_GIOVANNI.zip	FARM6CC747	SORGE GIOVANNI	Azienda Ospedaliero Universitaria Policlinico di Catania	Evaluation of enzyme replacement therapy with Naglazyme (Aryplase) on joint disease in mucopolysaccharidosis type VI patients.	50.000,00		
http://www.agenziafarmaco.gov.it/sites/default/files/44_TARONI_FRANCO.zip	FARM6H95MJ	TARONI FRANCO	Fondazione IRCCS Istituto Neurologico "Carlo Besta"	Randomized placebo-controlled double-blind trial to assess safety and efficacy of erythropoietin in adult patients with Friedreich's ataxia (a pilot study)	259.600,00		
http://www.agenziafarmaco.gov.it/sites/default/files/45_TERZOLO_MASSIMO.zip	FARM65BEM9	TERZOLO MASSIMO	Dipartimento di Scienze Cliniche e Biologiche, Università degli Studi di Torino	EFFICACY OF ADJUVANT MITOTANE TREATMENT IN PROLONGING DISEASE-FREE SURVIVAL IN PATIENTS WITH ADRENOCORTICAL CARCINOMA SUBMITTED TO RADICAL RESECTION	300.000,00		
http://www.agenziafarmaco.gov.it/sites/default/files/46_TOGNONI_GIOVANNI.zip	FARM6X822T	TOGNONI GIANNI	Consorzio Mario Negri Sud	Effects of the dose of erythropoiesis stimulating agents on cardiac-cerebrovascular outcomes and quality of life in hemodialysis patients. The DOSE of Erythropoietins (DOSE) trial	2.377.440,00	1.430.000,00	
http://www.agenziafarmaco.gov.it/sites/default/files/47_TONI_DANILO.zip	FARM65KNKY	TONI DANILO	Dipartimento Di Scienze Neurologiche – Università "La Sapienza" di Roma	A randomized controlled trial of alteplase (rt-PA) vs standard treatment in acute ischemic hemispheric stroke in patients aged more than 80 years, where thrombolysis is initiated within 3 hours after stroke onset	833.526,00		90.450,00
http://www.agenziafarmaco.gov.it/sites/default/files/48_VANNUCCHI_ALESSANDRO.zip	FARM6AKR9W	VANNUCCHI ALESSANDRO	Università degli Studi di Firenze, Dipartimento di Area Critica Medico	A PHASE 2 STUDY OF EFFICACY/SAFETY OF EVEROLIMUS IN SUBJECTS WITH IDIOPATHIC MYELOFIBROSIS (IMF)	200.000,00		

Link a Progetto e CV	Codice	Responsabile Scientifico	Istituzione	Titolo	Budget Indicato nel Contratto	Budget Ridotto per Riduzione Numerosità Campionaria	Extra Budget Autorizzato per Farmaco o Assicurazione
http://www.agenziafarmaco.gov.it/sites/default/files/49_VENTURA_ALESSANDRO.zip	FARM64J2EB	VENTURA ALESSANDRO	IRCCS "Burlo Garofolo"	RANDOMIZED CONTROLLED DOUBLE-BLIND VS. PLACEBO MULTICENTRE STUDY ON THE SAFETY AND EFFECTIVENESS OF THALIDOMIDE IN THE TREATMENT OF REFRACTORY CROHN'S DISEASE AND ULCERATIVE COLITIS IN CHILDREN AND ADOLESCENTS	222.300,00	200.070,00	
http://www.agenziafarmaco.gov.it/sites/default/files/50_ZANETTI_ALESSANDRO.zip	FARM67NFPN	ZANETTI ALESSANDRO	Università degli Studi di Milano	PERSISTENCE OF ANTI-HBs ANTIBODY AND OF IMMUNOLOGIC MEMORY FOR HEPATITIS B SURFACE ANTIGEN IN TWO COHORTS OF CHILDREN IMMUNISED WITH HEXAVALENT VACCINES: IMPLICATIONS FOR POLICY AND BOOSTER VACCINATION	363.000,00		